RMS Regrow's Chondron gets FDA approval

The Ministry of Health and DCGI have granted ‘Market Authorisation’ for ‘Cell Therapy’ product, Chondron ACI by Regenerative Medical Services Regrow. The announcement came from the CEO and MD of RMS Regrow, Yash Sanghavi on Thursday through a statement that said, “Chondron ACI is indicated for treatment of cartilage defects of the joints.

It uses the body's own autologous cartilage cells that are cultured and multiplied for three to four weeks at Regrow’s Cell Processing Centre. The cultured cells are then implanted into the patient's damaged joint leading to new cartilage regeneration, avoiding the need of early joint replacement.”

“We are immensely happy with the FDA approval. We are the first in the country and fourth in the world to achieve this FDA approval. We are creating new age cartilage regeneration procedure which optimizes the chances of healing due to the use of the body’s own cells. Patients can now expect a care free future with this treatment and RMS Regrow offers a perfect PEN solution,” he said.

Company’s Chief Scientific officer and Executive Director, Satyen Sanghavi said, “Today, knee pain is the most common ailment in every household. Osteoarthritis is the most prevalent form of arthritis, affecting over 15 million adults every year, with the number likely to escalate to over 60 million by 2025. Knee implants are expensive and the recovery of the cartilage is not fast. Chondron ACI has 97 per cent success rate with fast recovery, as observed in over five lakh cases performed worldwide.”